Acadia Pharmaceuticals Inc. reported its financial results for the first quarter ended March 31, 2025. The company achieved total revenues of $244.3 million, marking a 19% increase compared to the same period last year. Net product sales for NUPLAZID ® (pimavanserin) reached $159.7 million, representing a 23% year-over-year growth. Meanwhile, DAYBUE ® (trofinetide) recorded net product sales of $84.6 million, an 11% increase from the previous year. Acadia's net income for the first quarter was $19.0 million, or $0.11 per common share, compared to $16.6 million, or $0.10 per common share, in the first quarter of 2024. The company continues to expect full-year 2025 NUPLAZID net sales to be in the range of $650 to $690 million and DAYBUE net sales to range from $380 to $405 million. The company has accelerated the timeline for the COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, with topline results now anticipated in early Q4 2025. Acadia also highlighted its commitment to global expansion, having recently served the first patient outside the U.S. through a managed access program in the European Union.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.